Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07369154
PHASE3
52-week Open Label Safety-Tolerability Study
Sponsor: LB Pharmaceuticals Inc.
View on ClinicalTrials.gov
Summary
Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia
Official title: A 52 Week, Open Label Safety and Tolerability Study of LB-102 in Adult Patients With Schizophrenia
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
900
Start Date
2026-04
Completion Date
2029-04
Last Updated
2026-04-09
Healthy Volunteers
No
Conditions
Interventions
DRUG
LB-102
LB-102 flexible dosing 50 mg - 100 mg